Literature DB >> 19922739

Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities.

Bradley N Gaynes1.   

Abstract

Treatment-resistant depression (TRD) is a common clinical presentation responsible for much of the burden of major depressive disorder worldwide. For this reason, TRD requires aggressive identification and management. Although several models have been proposed to describe TRD, consensus is still needed on the criteria (ie, dose, duration, compliance, number of trials required) used to define treatment response and resistance. When diagnosing patients with depression, clinicians should identify risk factors associated with treatment resistance, including clinical subtypes of depression and medical or psychiatric comorbidities that could affect the course of treatment. When evaluating a patient who has not responded to a first course of antidepressant treatment, the clinician should verify the primary diagnosis and ensure that the patient has adhered to a treatment regimen that was of adequate dose and duration. Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922739     DOI: 10.4088/JCP.8133su1c.02

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

2.  Predictors of Poor Response to Depression Treatment in Primary Care.

Authors:  Rebecca C Rossom; Leif I Solberg; Gabriela Vazquez-Benitez; Robin R Whitebird; A Lauren Crain; Arne Beck; Jürgen Unützer
Journal:  Psychiatr Serv       Date:  2016-07-15       Impact factor: 3.084

3.  Dissociating pathomechanisms of depression with fMRI: bottom-up or top-down dysfunctions of the reward system.

Authors:  Roberto Goya-Maldonado; Kristina Weber; Sarah Trost; Esther Diekhof; Maria Keil; Peter Dechent; Oliver Gruber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-21       Impact factor: 5.270

4.  Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy.

Authors:  Larry Culpepper
Journal:  Prim Care Companion CNS Disord       Date:  2013-10-31

5.  Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients.

Authors:  Giovanni Camardese; Beniamino Leone; Riccardo Serrani; Coco Walstra; Marco Di Nicola; Giacomo Della Marca; Pietro Bria; Luigi Janiri
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-09       Impact factor: 2.570

6.  More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression.

Authors:  Taylor Lyons; Robin Lester Carhart-Harris
Journal:  Front Psychol       Date:  2018-10-12

Review 7.  Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.

Authors:  Nataliya Vorobyeva; Alena A Kozlova
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

8.  Online survey of medicinal cannabis users: Qualitative analysis of patient-level data.

Authors:  Albert Garcia-Romeu; Joshua Elmore; Rhiannon E Mayhugh; Nicolas J Schlienz; Erin L Martin; Justin C Strickland; Marcel Bonn-Miller; Heather Jackson; Ryan Vandrey
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

9.  How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?

Authors:  Jennifer Voelker; Kruti Joshi; Ella Daly; Eros Papademetriou; David Rotter; John J Sheehan; Harsh Kuvadia; Xing Liu; Anandaroop Dasgupta; Ravi Potluri
Journal:  Brain Behav       Date:  2021-01-05       Impact factor: 3.405

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.